- Defining year as partnerships progress on track
FY17 has been a defining year for Nuevolution as it looks to further validate its unique Chemetics drug discovery platform. Highlights include the Amgen development collaboration, out-licensing the RORγt inverse agonist (dermatology and psoriatic arthritis indications) to Almirall and the progression of the internally generated pipeline assets. We anticipate at least one further out-licensing or risk-sharing collaboration in FY18. We value the company's recent deals with Amgen, Almirall and Janssen at SEK902m ($113m). Our valuation does not include the technology, other pipeline assets and future deal opportunities.Nuevolution AB (publ). Nuevolution AB is a Sweden-based biopharmaceutical company working to develop future medicine for the treatment of cancer and inflammatory diseases. The Company's business is conducted through its wholly owned subsidiary, Nuevolution A/S.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.